Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × acalabrutinib × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 58 Other hematologic neoplasm 29 Gastrointestinal 2 Thoracic 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Classical hematology 1

Conditions

Carcinoma, Transitional Cell 1

Interventions

Docetaxel 191 Gemcitabine 147 Prednisone 142 pembrolizumab 124 enzalutamide 118 Abiraterone Acetate 108 Nivolumab 106 Cisplatin 102 Magnetic Resonance Spectroscopy 99 Sunitinib 94 Radiotherapy 94 Leuprolide 91 Carboplatin 82 Specimen Handling 70 Androgen Antagonists 62 Radiosurgery 61 Paclitaxel 60 bicalutamide 59 Goserelin 59 Ipilimumab 57 Bevacizumab 57 apalutamide 53 Sorafenib 53 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51 Everolimus 49 cabozantinib 48 atezolizumab 45 abiraterone 45 cabazitaxel 43 durvalumab 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351739 2019-09-10

KEYNOTE143

Acerta Pharma BV

Phase 2 Completed

78 enrolled 10 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡